Last reviewed · How we verify
RotaTeq™ existing formulation
RotaTeq is a live attenuated rotavirus vaccine that stimulates immune responses to prevent rotavirus gastroenteritis.
RotaTeq is a live attenuated rotavirus vaccine that stimulates immune responses to prevent rotavirus gastroenteritis. Used for Prevention of rotavirus gastroenteritis in infants and children.
At a glance
| Generic name | RotaTeq™ existing formulation |
|---|---|
| Also known as | V260 |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Live attenuated vaccine |
| Target | Rotavirus (multiple serotypes) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
RotaTeq contains five live reassortant rotavirus strains (derived from human and bovine rotavirus parents) that replicate in the intestinal tract and induce both humoral and mucosal immunity against rotavirus. The vaccine generates antibodies and cellular immune responses that protect against infection by wild-type rotavirus strains, preventing severe diarrheal disease in infants and young children.
Approved indications
- Prevention of rotavirus gastroenteritis in infants and children
Common side effects
- Diarrhea
- Vomiting
- Fever
- Irritability
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |